{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:56:51Z","timestamp":1790870211079,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recent randomized trials such as INSEMA and SOUND identified patients with breast cancer for whom axillary surgery omission appears to have no detrimental oncologic impact. However, some have questioned the safety of omitting axillary surgery in patients with invasive lobular carcinoma (ILC), the most common special histology type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed a prospectively maintained institutional ILC database containing 1029 tumor records. We identified those meeting INSEMA and SOUND criteria for axillary surgery omission (clinically node negative with axillary ultrasound, cT1-2 for INSEMA-eligible, cT1 for SOUND-eligible, no neoadjuvant therapy). We used chi-square and Wilcoxon rank-sum tests to evaluate factors associated with pathologic nodal positivity. Local and distant recurrence free survival for those omitting axillary surgery were explored using the Kaplan-Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 205 patients with ILC met preoperative criteria for the INSEMA or SOUND trials, of whom 189 (92%) underwent axillary surgery. Of 189 INSEMA-eligible patients, 19.8% were node positive and 30.2% upstaged in T category. Of 99 SOUND-eligible patients, 18.4% were node positive and 34.6% upstaged in T category. Younger age was significantly associated with nodal positivity (INSEMA\n                      <jats:italic>p<\/jats:italic>\n                      = 0.003, SOUND\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002). For the subset of patients who omitted axillary surgery, distant recurrence free survival was significantly worse compared to those who underwent axillary surgery in both INSEMA-eligible (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.001) and SOUND-eligible cohorts (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0495).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High rates of occult nodal positivity in ILC patients suggest the need for ILC-specific selection criteria for axillary surgery omission. Further studies are needed to evaluate potential impact on oncologic outcomes in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20144-y","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:51:16Z","timestamp":1783345876000},"page":"9781-9790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Omission of Axillary Surgery in Patients with Invasive Lobular Carcinoma of the Breast: Rates of Nodal Involvement in Clinically Node Negative Patients and Impact on Recurrence in a Single Institution Analysis"],"prefix":"10.1245","volume":"33","author":[{"given":"Elisabeth","family":"Abeles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Shui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Quirarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Barkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Huppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackelyn","family":"Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vertido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita A.","family":"Mukhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"11","key":"20144_CR1","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJMoa2412063","volume":"392","author":"T Reimer","year":"2025","unstructured":"Reimer T, Stachs A, Veselinovic K, et al. Axillary surgery in breast cancer - primary results of the INSEMA trial. N Engl J Med. 2025;392(11):1051\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2412063.","journal-title":"N Engl J Med."},{"issue":"11","key":"20144_CR2","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","volume":"9","author":"OD Gentilini","year":"2023","unstructured":"Gentilini OD, Botteri E, Sangalli C, et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. JAMA Oncol. 2023;9(11):1557\u201364. https:\/\/doi.org\/10.1001\/jamaoncol.2023.3759.","journal-title":"JAMA Oncol."},{"key":"20144_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/978-3-031-70875-6_14","volume":"1464","author":"E Bullock","year":"2025","unstructured":"Bullock E, Brunton VG. E-cadherin-mediated cell-cell adhesion and invasive lobular breast cancer. Adv Exp Med Biol. 2025;1464:259\u201375. https:\/\/doi.org\/10.1007\/978-3-031-70875-6_14.","journal-title":"Adv Exp Med Biol."},{"issue":"1","key":"20144_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1148\/rg.291085100","volume":"29","author":"JK Lopez","year":"2009","unstructured":"Lopez JK, Bassett LW. Invasive lobular carcinoma of the breast: spectrum of mammographic, US, and MR imaging findings. Radiographics. 2009;29(1):165\u201376. https:\/\/doi.org\/10.1148\/rg.291085100.","journal-title":"Radiographics."},{"issue":"11","key":"20144_CR5","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jnci\/djac157","volume":"114","author":"S Oesterreich","year":"2022","unstructured":"Oesterreich S, Nasrazadani A, Zou J, et al. Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer. J Natl Cancer Inst. 2022;114(11):1511\u201322. https:\/\/doi.org\/10.1093\/jnci\/djac157.","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"20144_CR6","doi-asserted-by":"publisher","first-page":"300060521101703","DOI":"10.1177\/03000605211017039","volume":"49","author":"S Danzinger","year":"2021","unstructured":"Danzinger S, Hielscher N, Izs\u00f3 M, et al. Invasive lobular carcinoma: clinicopathological features and subtypes. J Int Med Res. 2021;49(6):3000605211017039. https:\/\/doi.org\/10.1177\/03000605211017039.","journal-title":"J Int Med Res."},{"key":"20144_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103001","volume":"140","author":"G Corso","year":"2025","unstructured":"Corso G, Shen S, Criscitiello C, et al. Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group. Cancer Treat Rev. 2025;140:103001. https:\/\/doi.org\/10.1016\/j.ctrv.2025.103001.","journal-title":"Cancer Treat Rev."},{"key":"20144_CR8","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-026-19387-6","author":"L Scardina","year":"2026","unstructured":"Scardina L, D\u2019Archi S, Accetta C, et al. Axillary nodal positivity in early-stage invasive lobular carcinoma: implications for sentinel lymph node biopsy omission. Ann Surg Oncol. 2026. https:\/\/doi.org\/10.1245\/s10434-026-19387-6.","journal-title":"Ann Surg Oncol."},{"key":"20144_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-88443-1","volume-title":"AJCC cancer staging manual","author":"American Joint Committee on Cancer","year":"2010","unstructured":"American Joint Committee on Cancer. AJCC cancer staging manual. 7th edn. Berlin: Springer; 2010.","edition":"7"},{"issue":"3","key":"20144_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10549-020-06047-w","volume":"185","author":"K Schumacher","year":"2021","unstructured":"Schumacher K, Inciardi M, O\u2019Neil M, et al. Is axillary imaging for invasive lobular carcinoma accurate in determining clinical node staging? Breast Cancer Res Treat. 2021;185(3):567\u201372. https:\/\/doi.org\/10.1007\/s10549-020-06047-w.","journal-title":"Breast Cancer Res Treat."},{"issue":"10","key":"20144_CR11","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1245\/s10434-021-10455-7","volume":"28","author":"D Cocco","year":"2021","unstructured":"Cocco D, ElSherif A, Wright MD, et al. Invasive lobular breast cancer: data to support surgical decision making. Ann Surg Oncol. 2021;28(10):5723\u20139. https:\/\/doi.org\/10.1245\/s10434-021-10455-7.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"20144_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2214\/AJR.21.26135","volume":"218","author":"HL Chung","year":"2022","unstructured":"Chung HL, Tso HH, Middleton LP, Sun J, Leung JWT. Axillary nodal metastases in invasive lobular carcinoma versus invasive ductal carcinoma: comparison of node detection and morphology by ultrasound. AJR Am J Roentgenol. 2022;218(1):33\u201341. https:\/\/doi.org\/10.2214\/AJR.21.26135.","journal-title":"AJR Am J Roentgenol."},{"issue":"7","key":"20144_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.ejso.2014.03.026","volume":"40","author":"A Topps","year":"2014","unstructured":"Topps A, Clay V, Absar M, et al. The sensitivity of pre-operative axillary staging in breast cancer: comparison of invasive lobular and ductal carcinoma. Eur J Surg Oncol. 2014;40(7):813\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2014.03.026.","journal-title":"Eur J Surg Oncol."},{"issue":"8","key":"20144_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/bjs.10791","volume":"105","author":"E Morrow","year":"2018","unstructured":"Morrow E, Lannigan A, Doughty J, et al. Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast. Br J Surg. 2018;105(8):987\u201395. https:\/\/doi.org\/10.1002\/bjs.10791.","journal-title":"Br J Surg."},{"issue":"5","key":"20144_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/s1072-7515(00)00257-x","volume":"190","author":"C Gajdos","year":"2000","unstructured":"Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST. Stage 0 to stage III breast cancer in young women. J Am Coll Surg. 2000;190(5):523\u20139. https:\/\/doi.org\/10.1016\/s1072-7515(00)00257-x.","journal-title":"J Am Coll Surg."},{"issue":"5","key":"20144_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1097\/00000658-199911000-00012","volume":"230","author":"C Gajdos","year":"1999","unstructured":"Gajdos C, Tartter PI, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg. 1999;230(5):692\u20136. https:\/\/doi.org\/10.1097\/00000658-199911000-00012.","journal-title":"Ann Surg."},{"issue":"1","key":"20144_CR17","doi-asserted-by":"publisher","first-page":"14340","DOI":"10.1038\/s41598-021-93676-w","volume":"11","author":"H Abdel-Razeq","year":"2021","unstructured":"Abdel-Razeq H, Iweir S, Abdel-Razeq R, et al. Differences in clinicopathological characteristics, treatment, and survival outcomes between older and younger breast cancer patients. Sci Rep. 2021;11(1):14340. https:\/\/doi.org\/10.1038\/s41598-021-93676-w.","journal-title":"Sci Rep."},{"key":"20144_CR18","unstructured":"Guidelines detail. NCCN. Accessed March 31, 2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1419."},{"issue":"14","key":"20144_CR19","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1200\/JCO-25-00099","volume":"43","author":"KU Park","year":"2025","unstructured":"Park KU, Somerfield MR, Anne N, et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2025;43(14):1720\u201341. https:\/\/doi.org\/10.1200\/JCO-25-00099.","journal-title":"J Clin Oncol."},{"issue":"3","key":"20144_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/jbi\/wbab015","volume":"3","author":"KK Hovis","year":"2021","unstructured":"Hovis KK, Lee JM, Hippe DS, et al. Accuracy of preoperative breast MRI versus conventional imaging in measuring pathologic extent of invasive lobular carcinoma. J Breast Imaging. 2021;3(3):288\u201398. https:\/\/doi.org\/10.1093\/jbi\/wbab015.","journal-title":"J Breast Imaging."},{"issue":"4","key":"20144_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.amjsurg.2019.07.016","volume":"218","author":"JK Plichta","year":"2019","unstructured":"Plichta JK, Thomas SM, Sergesketter AR, et al. Clinical and pathological stage discordance among 433,514 breast cancer patients. Am J Surg. 2019;218(4):669\u201376. https:\/\/doi.org\/10.1016\/j.amjsurg.2019.07.016.","journal-title":"Am J Surg."},{"issue":"12","key":"20144_CR22","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.22.01565","volume":"41","author":"SAL Bartels","year":"2023","unstructured":"Bartels SAL, Donker M, Poncet C, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981\u201322023 AMAROS trial. J Clin Oncol. 2023;41(12):2159\u201365. https:\/\/doi.org\/10.1200\/JCO.22.01565.","journal-title":"J Clin Oncol."},{"issue":"34","key":"20144_CR23","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987\u201398. https:\/\/doi.org\/10.1200\/JCO.20.02514.","journal-title":"J Clin Oncol."},{"issue":"12","key":"20144_CR24","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390(12):1080\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2305488.","journal-title":"N Engl J Med."},{"issue":"1","key":"20144_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1245\/s10434-023-14474-4","volume":"31","author":"RA Mukhtar","year":"2024","unstructured":"Mukhtar RA, Huppert L, Ramalingam K. Letter to the editor of Annals of Surgical Oncology concerning \"Is Choosing Wisely wise for lobular carcinoma in patients over 70 years of age? A national cancer database analysis of sentinel node practice patterns\u201d. Ann Surg Oncol. 2024;31(1):401\u20132. https:\/\/doi.org\/10.1245\/s10434-023-14474-4.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"20144_CR26","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1245\/s10434-022-12003-3","volume":"29","author":"N Carleton","year":"2022","unstructured":"Carleton N, Oesterreich S, Marroquin OC, et al. Is the Choosing Wisely recommendation for omission of sentinel lymph node biopsy applicable for invasive lobular carcinoma? Ann Surg Oncol. 2022;29(9):5379\u201382. https:\/\/doi.org\/10.1245\/s10434-022-12003-3.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"20144_CR27","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1245\/s10434-023-13886-6","volume":"30","author":"NH Goldhaber","year":"2023","unstructured":"Goldhaber NH, O\u2019Keefe T, Kang J, Douglas S, Blair SL. Is Choosing Wisely wise for lobular carcinoma in patients over 70 years of age? A national cancer database analysis of sentinel node practice patterns. Ann Surg Oncol. 2023;30(10):6024\u201332. https:\/\/doi.org\/10.1245\/s10434-023-13886-6.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"20144_CR28","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.soc.2022.06.001","volume":"31","author":"K Goodman","year":"2022","unstructured":"Goodman K, Abel MK, Lawhn-Heath C, Molina-Vega J, Jones EF, Mukhtar RA. Molecular imaging for estrogen receptor-positive breast cancer: clinical applications of whole body and dedicated breast positron emission tomography. Surg Oncol Clin N Am. 2022;31(4):569\u201379. https:\/\/doi.org\/10.1016\/j.soc.2022.06.001.","journal-title":"Surg Oncol Clin N Am."},{"key":"20144_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-026-02277-w","author":"KM Switalla","year":"2026","unstructured":"Switalla KM, Onishi N, Jones EF, et al. A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy. Breast Cancer Res. 2026. https:\/\/doi.org\/10.1186\/s13058-026-02277-w.","journal-title":"Breast Cancer Res."},{"issue":"22","key":"20144_CR30","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.3390\/cancers15225491","volume":"15","author":"H Batra","year":"2023","unstructured":"Batra H, Mouabbi JA, Ding Q, Sahin AA, Raso MG. Lobular carcinoma of the breast: a comprehensive review with translational insights. Cancers (Basel). 2023;15(22):5491. https:\/\/doi.org\/10.3390\/cancers15225491.","journal-title":"Cancers (Basel)."},{"issue":"10","key":"20144_CR31","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.1245\/s10434-023-13909-2","volume":"30","author":"HT Rothschild","year":"2023","unstructured":"Rothschild HT, Mukhtar RA. ASO author reflections: patient, tumor, and treatment characteristics predict early versus late recurrence in patients with invasive lobular carcinoma of the breast. Ann Surg Oncol. 2023;30(10):6008\u20139. https:\/\/doi.org\/10.1245\/s10434-023-13909-2.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20144-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20144-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20144-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:15:25Z","timestamp":1790867725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20144-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20144"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20144-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LH discloses the following: Adboard\/consulting: Boehringer Ingelheim; Research funding to institution: Genentech, Gilead, Greenwich LifeSciences, Johnson&Johnson, Merck, Mersana, Pfizer; Travel to academic meeting: Daiichi Sankyo; Book royalties: McGraw Hill. RAM discloses research funding from GE Healthcare.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}